Centre Hospitalier Régional Universitaire
Besançon, 25030, France
NCT Number: NCT03056404
This study aims at identifying bird proteins useful for diagnostic tests to determine the cause of Bird Fancier's Lung (BFL).
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Besançon, 25030, France
Allergic diseases are an important part of health concerns in Europe and in countries "industrialized". Among them are distinguished from hypersensitivity pneumonitis (HP), consecutive to repeated inhalation of organic substances (bacteria, fungi, avian proteins ...).
As with other HP, the BFL is a invalidating disease, but usually not lethal if the patient reduced sufficiently early exposure to antigens.
Associated symptoms include breathing difficulties a dry cough, a general fatigued state accompanied by a fever and a rapid and pronounced weight loss.
These clinical signs may be similar to a flu-like condition, difficult to discern from other respiratory disease. Diagnosis is based on a set of clinical, radiological and biological arguments that are often discussed.
Using these criteria as predictors would increase opportunities to diagnose HP without using invasive clinical examinations such as biopsy and bronchoalveolar lavage.
Although serology is a useful argument for the diagnosis, its value is often criticized.
Thus, significant variations in performance of serological tests are observed from one provider to another and, for the same supplier, from one batch to another.
This issue could be raised by the use of recombinant antigens. The principle is to use only to the reaction the purified protein of interest produced by genetic engineering.
The Parasitology-Mycology department has acquired expertise in the research of proteins of interest for serology allergic diseases and in the manufacture of recombinant antigens. Thus the work of the team have identified proteins of interest for the diagnosis of two HP of occupational origin and translates this expertise to identify pigeon's proteins and study the feasibility of this research.
For this project, the pigeon droppings (Columba livia), collected from different breeders in the region were identified as antigenic source.
The objective of the HYPERSENS project is to extend the problematic to other species of birds and understand the specific species of antigenic proteins. The aim is also to identify and produce recombinant proteins that will identify the cause of avian hypersensitivity pneumonitis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 months
5 and 15 proteins for all selected birds
Time frame: 24 months
Identifying at least three specific proteins for each bird species by 2D-Electrophoresis and Western blotting (based on previous study).
Time frame: 24 months
Identifying at least one common protein to all droppings of selected bird species by 2D-Electrophoresis and Western blotting. This protein will be recognized by the antibodies of all patients regardless of their exposure and not recognized by controls. It would make the diagnosis of BFL for any avian exposure.
Centre Hospitalier Universitaire de Besancon
Other
Acronym: HYPERSENS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03747627
Alveolitis, Extrinsic Allergic, Bird Fancier's Lung
Blackpool, United Kingdom
View Trial DetailsNCT06727825
Asthma, Asthma, Occupational
Créteil, France
View Trial DetailsNCT06457269
Actinomycetales Infections, Acute Bronchitis
Nanchong, Sichuan, China
View Trial DetailsNCT06179342
Asthma, Bronchial Diseases
Solingen, North Rhine-Westphalia, Germany
View Trial Details